Opella is now a standalone company. Sanofi announced today the closing of the sale to CD&R of a 50.0% controlling stake of ...

Edema is a medical condition characterized by the accumulation of excess fluid in the body’s tissues, leading to swelling and ...

The Interventional Oncology Market is poised for significant growth, projected to reach USD 3.9 billion by 2025, expanding at ...

Hiring the right Laravel development company is not just about technical skills. It's about finding a team that understands ...

Introduction: The Convergence of AI and Life SciencesTraditionally, drug discovery is a time-consuming and costly process, ...

European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive recommendation ...

NCIMB Limited ("NCIMB"), a leading microbiology services provider and owner of the UK’s largest industrial, food and marine bacterial culture collection, has secured a £1.7m investment from the ...

Cycuria aims to revolutionise treatment of hard-to-treat blood cancers with a first-in-class protein-based therapeutic approach specifically targeting both tumour cells and tumour stem cells·    ...

The Novo Nordisk Foundation today announced the latest edition of its annual Challenge Programme, where for the first time it is inviting researchers from outside Denmark, in the European Schengen ...

First results from SunRISe-1 (Cohort 4) show strong disease-free survival rates across high-grade papillary tumours, demonstrating the potential for bladder preservation with 94 percent of patients ...

Urcosimod phase 2 trial treating Neuropathic Corneal Pain (“NCP”) patients was initiated in October 2024 and designed as a double-masked, randomized, 12-week placebo-controlled trial.OKYO Pharma plans ...

RetinAI US Inc. (RetinAI) and      Fundación Ver Salud (FVS) are pleased to jointly announce that LuxIA®, their co-developed innovative AI algorithm for Diabetic Retinopathy (DR) screening, has ...